[
Biomarkers
Epithelial-mesenchymal transition
Number of lesions
Oligometastatic PCa
Radiomics
Silhouette index
Similarity analysis
[18F]FMCH PET/CT
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
27 Nov 2021
27 Nov 2021
Historique:
received:
27
06
2021
accepted:
04
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [ PCa patients eligible for [ [ We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.
Sections du résumé
BACKGROUND
BACKGROUND
The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [
METHODS
METHODS
PCa patients eligible for [
RESULTS
RESULTS
[
CONCLUSIONS
CONCLUSIONS
We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.
Identifiants
pubmed: 34837532
doi: 10.1186/s13550-021-00858-8
pii: 10.1186/s13550-021-00858-8
pmc: PMC8627538
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119Subventions
Organisme : associazione italiana per la ricerca sul cancro
ID : AIRC IG 2017 Id. 20819
Informations de copyright
© 2021. The Author(s).
Références
Eur J Radiol. 2012 Aug;81(8):e893-6
pubmed: 22621862
Diagnostics (Basel). 2020 May 30;10(6):
pubmed: 32486314
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
PLoS Comput Biol. 2018 Jan 2;14(1):e1005914
pubmed: 29293497
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Semin Cancer Biol. 2020 Dec 5;:
pubmed: 33290846
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):185-191
pubmed: 31620808
Radiat Oncol. 2016 Jan 22;11:9
pubmed: 26796633
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):301-9
pubmed: 19756592
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
Oncotarget. 2015 Apr 20;6(11):8491-524
pubmed: 25940699
Sci Rep. 2020 Feb 26;10(1):3490
pubmed: 32103057
Lancet Oncol. 2013 Jan;14(1):e28-37
pubmed: 23276369
Mol Cancer Res. 2019 Apr;17(4):949-962
pubmed: 30647103
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur Urol. 2017 Aug;72(2):289-292
pubmed: 27574820
Eur J Hybrid Imaging. 2020 Jun 1;4(1):9
pubmed: 34191173
J Urol. 2010 Sep;184(3):938-43
pubmed: 20643445
Eur Urol. 2016 Jan;69(1):13-4
pubmed: 26283009
Clin Genitourin Cancer. 2013 Mar;11(1):27-32
pubmed: 23010414
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1293-1301
pubmed: 33150459
Eur J Hybrid Imaging. 2020 Dec 9;4(1):24
pubmed: 34191197
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2737-2745
pubmed: 31690962
Nat Rev Urol. 2017 Jan;14(1):15-25
pubmed: 27725639
J Med Imaging Radiat Oncol. 2018 Oct;62(5):692-706
pubmed: 29808571
Front Oncol. 2020 Jan 31;10:55
pubmed: 32083008
World J Urol. 2019 Nov;37(11):2343-2353
pubmed: 30706122
Oncol Res Treat. 2016;39(4):217-20
pubmed: 27160394
Anticancer Res. 2018 May;38(5):3119-3122
pubmed: 29715150
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839